A clinical trail to investigate the influence of SLCO2B1 polymorphism on the pharmacokinetic characteristics of voriconazole in CYP2C19 poor metabolizers

NCT02906176

Conditions

1. Healthy Volunteers

Interventions

1. Drug: Vfend (voriconazole) intravenous infusion
2. Drug: Vfend (voriconazole) tablet

Inclusion Criteria: - Healthy male volunteer who is a CYP2C19 Poor metabolizer with rs3781727 SNP wild or variant genotype Exclusion Criteria: - History of clinically significant respiratory, cardiovascular, renal, hepatic, hematologic, neurological disorder Inclusion Criteria: - Healthy male volunteer who is a CYP2C19 Poor metabolizer with rs3781727 SNP wild or variant genotype Exclusion Criteria: - History of clinically significant respiratory, cardiovascular, renal, hepatic, hematologic, neurological disorder Healthy Volunteers null